Advertisement

Breast Cancer Medications

Here's a list of the approved drugs to treat breast cancer. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG RECOMMENDATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Arimidex
GENERIC NAME anastrozole
DRUG RECOMMENDATION

Arimidex is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and first-line or subsequent treatment of HR+ advanced or metastatic breast cancer in postmenopausal women.

DRUG Aromasin
GENERIC NAME exemestane
DRUG RECOMMENDATION

Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.

DRUG Evista
GENERIC NAME raloxifene
DRUG RECOMMENDATION

Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.

DRUG Fareston
GENERIC NAME toremifene
DRUG RECOMMENDATION

Fareston is a selective estrogen receptor modulator approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors or those with unknown receptor status.

DRUG Faslodex
GENERIC NAME fulvestrant
DRUG RECOMMENDATION

Faslodex is an estrogen receptor downregulator approved for the treatment of hormone receptor-positive advanced or metastatic breast cancer in postmenopausal women.

DRUG Femara
GENERIC NAME letrozole
DRUG RECOMMENDATION

Femara is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of hormone receptor-positive (HR+) early breast cancer and treatment of HR+ advanced breast cancer in postmenopausal women.

DRUG Lupron
GENERIC NAME leuprolide
DRUG RECOMMENDATION

Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

DRUG Tamoxifen
GENERIC NAME tamoxifen
DRUG RECOMMENDATION

Tamoxifen is a selective estrogen receptor modulator approved for adjuvant (post-surgery) treatment to prevent recurrence or spread of early breast cancer and for treatment of women and men with advanced or metastatic breast cancer. It is also used to prevent breast cancer in high-risk women. It is sometimes used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Zoladex
GENERIC NAME goserelin
DRUG RECOMMENDATION

Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG RECOMMENDATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, liver cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Opdivo
GENERIC NAME nivolumab
DRUG RECOMMENDATION

Opdivo is a checkpoint inhibitor approved for advanced or metastatic melanoma, metastatic non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, metastatic bladder (urothelial) cancer, liver cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Afinitor
GENERIC NAME everolimus
DRUG RECOMMENDATION

Afinitor is a kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in previously treated postmenopausal women, as well as for advanced kidney cancer and advanced or metastatic neuroendocrine tumors of the lung, pancreas, and gastrointestinal tract.

DRUG Herceptin
GENERIC NAME trastuzumab
DRUG RECOMMENDATION

Herceptin is a HER2 inhibitor approved for adjuvant (post-surgery) therapy of early breast cancer and treatment of metastatic breast cancer and gastric or esophageal carcinoma that overexpresses human epidermal growth factor receptor 2.

DRUG Ibrance
GENERIC NAME palbociclib
DRUG RECOMMENDATION

Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Kadcyla
GENERIC NAME ado-trastuzumab emtansine
DRUG RECOMMENDATION

Kadcyla is a HER2 inhibitor combined with a chemotherapy drug. It is approved for people with HER2-positive metastatic breast cancer who were previously treated with Herceptin and chemotherapy.

DRUG Kisqali
GENERIC NAME ribociclib
DRUG RECOMMENDATION

Kisqali is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

DRUG Lynparza
GENERIC NAME olaparib
DRUG RECOMMENDATION

Lynparza is a PARP inhibitor approved for first-line maintenance treatment of ovarian cancer in women with harmful BRCA mutations, maintenance treatment of recurrent ovarian cancer that is responding to chemotherapy, previously treated advanced ovarian cancer in patients with BRCA mutations, and previously treated HER2-negative metastatic breast cancer in people with BRCA mutations.

DRUG Nerlynx
GENERIC NAME neratinib
DRUG RECOMMENDATION

Nerlynx is a kinase inhibitor approved for extended adjuvant (post-surgery) treatment of early breast cancer that overexpresses human epidermal growth factor receptor 2 in people who previously used Herceptin.

DRUG Perjeta
GENERIC NAME pertuzumab
DRUG RECOMMENDATION

Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.

DRUG Talzenna
GENERIC NAME talazoparib
DRUG RECOMMENDATION

Talzenna is a PARP inhibitor approved for HER2 negative locally advanced or metastatic breast cancer in people with harmful BRCA mutations.

DRUG Tykerb
GENERIC NAME lapatanib
DRUG RECOMMENDATION

Tykerb is a kinase inhibitor approved in combination with chemotherapy for previously treated patients with HER2-positive metastatic breast cancer. It is also approved in combination with hormone therapy for postmenopausal women with both HER2-positive and hormone receptor-positive metastatic cancer.

DRUG Verzenio
GENERIC NAME abemaciclib
DRUG RECOMMENDATION

Verzenio is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, alone or in combination with hormone therapy.

DRUG Vitrakvi
GENERIC NAME larotrectinib
DRUG RECOMMENDATION

Vitrakvi is a tropomyosin receptor kinase (TRK) inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

Advertisement

Hot topics